ドロンダロン
- ¥430000 - ¥1080000
- 化學(xué)名: ドロンダロン
- 英語名: Dronedarone
- 別名:ドロンダロン;ドロネダロン;N-[2-ブチル-3-[4-[3-(ジブチルアミノ)プロポキシ]ベンゾイル]ベンゾフラン-5-イル]メタンスルホンアミド;[2-ブチル-5-(メチルスルホニルアミノ)ベンゾフラン-3-イル][4-[3-(ジブチルアミノ)プロポキシ]フェニル]ケトン;N-(2-ブチル-3-{4-[3-(ジブチルアミノ)プロポキシ]ベンゾイル}-1-ベンゾフラン-5-イル)メタンスルホンアミド
- CAS番號(hào): 141626-36-0
- 分子式: C31H44N2O5S
- 分子量: 556.76
- EINECS:
- MDL Number:MFCD00910331
2物価
選択條件:
ブランド
- 富士フイルム和光純薬株式會(huì)社(wako)
パッケージ
- 250mg
- 1g
- 生産者富士フイルム和光純薬株式會(huì)社(wako)
- 製品番號(hào)W01COBQJ-9999
- 製品説明ドロンダロン
- 英語製品説明Dronedarone
- 包裝単位250mg
- 価格¥430000
- 更新しました2024-03-01
- 購入
- 生産者富士フイルム和光純薬株式會(huì)社(wako)
- 製品番號(hào)W01COBQJ-9999
- 製品説明ドロンダロン
- 英語製品説明Dronedarone
- 包裝単位1g
- 価格¥1080000
- 更新しました2024-03-01
- 購入
生産者 | 製品番號(hào) | 製品説明 | 包裝単位 | 価格 | 更新時(shí)間 | 購入 |
---|---|---|---|---|---|---|
富士フイルム和光純薬株式會(huì)社(wako) | W01COBQJ-9999 | ドロンダロン Dronedarone |
250mg | ¥430000 | 2024-03-01 | 購入 |
富士フイルム和光純薬株式會(huì)社(wako) | W01COBQJ-9999 | ドロンダロン Dronedarone |
1g | ¥1080000 | 2024-03-01 | 購入 |
プロパティ
融點(diǎn) :65.3°
沸點(diǎn) :683.9±65.0 °C(Predicted)
比重(密度) :1.143±0.06 g/cm3(Predicted)
貯蔵溫度 :2-8°C
溶解性 :≥27.84 mg/mL in DMSO; insoluble in H2O; ≥49.8 mg/mL in EtOH
外見 :solid
酸解離定數(shù)(Pka) :7.40±0.30(Predicted)
色 :White to off-white
CAS データベース :141626-36-0(CAS DataBase Reference)
沸點(diǎn) :683.9±65.0 °C(Predicted)
比重(密度) :1.143±0.06 g/cm3(Predicted)
貯蔵溫度 :2-8°C
溶解性 :≥27.84 mg/mL in DMSO; insoluble in H2O; ≥49.8 mg/mL in EtOH
外見 :solid
酸解離定數(shù)(Pka) :7.40±0.30(Predicted)
色 :White to off-white
CAS データベース :141626-36-0(CAS DataBase Reference)
安全情報(bào)
絵表示(GHS): | |||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
注意喚起語: | Warning | ||||||||||||||||||||||||||||||||||||||||||
危険有害性情報(bào): |
|
||||||||||||||||||||||||||||||||||||||||||
注意書き: |
|
説明
AF is the most common form of sustained cardiac arrhythmia, with an increasing prevalence in the aging population. AF accounts for 34.5% of arrhythmia-related hospital admissions in the United States. The most significant consequences of AF include congestive heart failure, a 5-fold increased risk of stroke, and increased rate of mortality. Although a 90% conversion rate from AF to normal sinus rhythm (NSR) can be achieved with electrical cardioversion, up to 70% of these patients require additional therapy with antiarrhythmic drugs in order to maintain NSR.Dronedarone, a close analog of amiodarone, is structurally modified to provide improved safety and pharmacokinetic profile. With the introduction of a sulfonamide group, dronedarone is less lipophilic, has lower tissue accumulation, and has a much shorter serum half-life (~24 h) compared with amiodarone. Additionally, dronedarone lacks the iodine moieties that are responsible for thyroid dysfunctions associated with amiodarone. Dronedarone is specifically indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent AF or AFL, with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted. Similar to amiodarone, dronedarone is a potent blocker of multiple ion currents (including the rapidly activating delayed-rectifier potassium current, the slowly activating delayed-rectifier potassium current, the inward rectifier potassium current, the acetylcholine-activated potassium current, peak sodium current, and L-type calcium current) and exhibits antiadrenergic effects. Overall, dronedarone was well tolerated. The most common side effects were gastrointestinal in nature and included nausea, vomiting, and diarrhea.